MDxHealth (NASDAQ:MDXH) Trading Up 5.7%

MDxHealth SA (NASDAQ:MDXH)’s share price was up 5.7% on Friday . The company traded as high as $3.20 and last traded at $3.14. Approximately 169,392 shares were traded during trading, an increase of 119% from the average daily volume of 77,173 shares. The stock had previously closed at $2.97.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MDXH. William Blair restated an “outperform” rating on shares of MDxHealth in a research note on Thursday, March 7th. BTIG Research lifted their price objective on shares of MDxHealth from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday, March 7th. Finally, Piper Sandler boosted their price objective on shares of MDxHealth from $6.00 to $7.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th.

MDxHealth Stock Performance

The company has a 50-day moving average of $2.78 and a 200-day moving average of $13.34.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.39) EPS for the quarter. The company had revenue of $19.40 million for the quarter. Equities analysts predict that MDxHealth SA will post -1.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors and hedge funds have recently modified their holdings of the company. Perkins Capital Management Inc. increased its holdings in MDxHealth by 2.7% in the fourth quarter. Perkins Capital Management Inc. now owns 415,225 shares of the company’s stock valued at $1,636,000 after buying an additional 11,000 shares in the last quarter. MVM Partners LLC purchased a new position in shares of MDxHealth during the 4th quarter valued at approximately $17,906,000. Finally, FAS Wealth Partners Inc. acquired a new stake in MDxHealth in the 1st quarter valued at $42,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications.